AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
QIAGEN N.V.
XNYS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001S91B01
50.39▲ 0.17 (0.34%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
50.22
Day's Range
50.33 – 50.45
52-Week Range
32.53 – 57.82
Volume
7.1M
Avg Volume
4.2M
Share Statistics
Shares Outstanding
Employees
5,654
Exchange
XNYS
Listed
1996-06-28
Share count as of January 31, 2026

QIAGEN N.V. (QGEN) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about QIAGEN N.V. (QGEN)
What is QIAGEN N.V.'s Market Cap?
QIAGEN N.V.'s Market Cap is $10.4B, based on as-reported figures from SEC (XBRL) filings.
What is QIAGEN N.V.'s Enterprise Value?
QIAGEN N.V.'s Enterprise Value is $11.0B, based on as-reported figures from SEC (XBRL) filings.
What is QIAGEN N.V.'s Trailing P/E?
QIAGEN N.V.'s Trailing P/E is 24.5×, based on as-reported figures from SEC (XBRL) filings.
What is QIAGEN N.V.'s Price / Sales?
QIAGEN N.V.'s Price / Sales is 5.0×, based on as-reported figures from SEC (XBRL) filings.
What is QIAGEN N.V.'s EV / Revenue?
QIAGEN N.V.'s EV / Revenue is 5.3×, based on as-reported figures from SEC (XBRL) filings.
What is QIAGEN N.V.'s EV / EBITDA?
QIAGEN N.V.'s EV / EBITDA is 17.4×, based on as-reported figures from SEC (XBRL) filings.
What is QIAGEN N.V.'s Revenue (TTM)?
QIAGEN N.V.'s Revenue (TTM) is $2.1B, based on as-reported figures from SEC (XBRL) filings.
What is QIAGEN N.V.'s Net Income (TTM)?
QIAGEN N.V.'s Net Income (TTM) is $424.9M, based on as-reported figures from SEC (XBRL) filings.
What is QIAGEN N.V.'s EBITDA?
QIAGEN N.V.'s EBITDA is $659.6M, based on as-reported figures from SEC (XBRL) filings.
What is QIAGEN N.V.'s Diluted EPS (TTM)?
QIAGEN N.V.'s Diluted EPS (TTM) is 2.05, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · QGENAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017
Net sales
YoY growth+5.7%
Cost of sales:
Cost of sales
Acquisition-related intangible amortization
Total cost of sales
Gross profit
% of revenue62.2%
Operating expenses:
Sales and marketing
Research and development
General and administrative
Acquisition-related intangible amortization
Restructuring, acquisition, integration and other, net
Total operating expenses
% of revenue39.9%
Income from operations
% of revenue22.3%
Other income (expense):
Interest income
Interest expense
Other expense, net
Total other income, net
Income before income tax expense
Income tax expense
Net income
% of revenue20.3%
Basic earnings per common share (in USD per share)
Diluted earnings per common share (in USD per share)